SCHEMBL10275596

SCHEMBL10275596

Cc1nn2c(c1-c1ccc(F)cc1F)C(c1ccc(C(F)(F)F)cc1)=NC2=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.38
NR3C2 P08235 1/20 0.38
OPRM1 P35372 1/20 0.36
APP P05067 1/20 0.36
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
NPSR1 Q6W5P4 2/20 0.34
KDM4E B2RXH2 1/20 0.34
PDE2A O00408 2/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
GPBAR1 Q8TDU6 1/20 0.33
PTGS2 P35354 1/20 0.33
GPR52 Q9Y2T5 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
GAA P10253 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10276114 0.92 PGR (0.39) PGRNR3C2OPRM1APPPDE3B
SCHEMBL10313507 0.89 PGR (0.40) PGRNR3C2OPRM1PDE3BPDE3A
SCHEMBL10275939 0.87 PGR (0.39) PGRNR3C2OPRM1PDE3BPDE3A
SCHEMBL10275213 0.87 APP (0.36) APPPDE3BPDE3ANPSR1KDM4E
SCHEMBL10276342 0.85 NPSR1 (0.44) APPNPSR1KDM4ESRCBRAF
SCHEMBL10275622 0.85 PDE4A (0.38) PGRNR3C2OPRM1KDM4EHPGD
SCHEMBL10275390 0.84 AR (0.37) PGRNR3C2OPRM1PDE3BPDE3A
SCHEMBL10275758 0.84 PDE2A (0.40) KDM4EPDE2ABRAFNPC1MAPT
SCHEMBL10276440 0.83 OPRM1 (0.38) PGRNR3C2OPRM1APPPDE3B
SCHEMBL10276100 0.82 KIF11 (0.39) PDE3BPDE3ANPSR1KDM4EALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US claimed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 PGR 3472/4885NR3C2 1731/4885OPRM1 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.